Emiko Sugiyama
Papers
1
Total Citations
35
H-Index
1
About
Dr. Emiko Sugiyama is a translational cancer researcher whose work focuses on improving therapeutic outcomes for pancreatic cancer, one of the most lethal malignancies. Her primary research areas include predictive biomarker discovery, pharmacoproteomics, and personalized medicine in oncology. Dr. Sugiyama’s most cited study, “Survival Prediction for Pancreatic Cancer Patients Receiving Gemcitabine Treatment” (2010, 35 citations), exemplifies her major contribution: using liquid chromatography-mass spectrometry (LC-MS) to identify protein biomarkers that can forecast which patients will benefit from gemcitabine monotherapy—a standard but variably effective treatment. By revealing that a significant subset of patients derive little benefit, her work underscores the urgent need for tailored therapeutic strategies. This research has directly influenced efforts to reduce unnecessary toxicity and improve survival prediction in clinical settings. Dr. Sugiyama’s achievements are notable for bridging advanced proteomic techniques with real-world clinical challenges, offering a pathway toward more precise, patient-specific cancer care. Her findings continue to inform biomarker-driven trials and represent a critical step in moving beyond one-size-fits-all chemotherapy.
Research Focus
Key Achievements
Top Papers
- 1